Excessive weight has been a persistent problem in America, where at least one in five adults in each U.S. state is living ...

Scientists know the stomach talks to the brain, but two new studies from Rutgers Health researchers suggest the conversation ...

(Corrects paragraph 3 to say 36 days, not 36 weeks) (Reuters) -Shares of weight-loss drug developer Metsera gained as much as 25% on Monday after the company's experimental drug helped patients lose ...

Semaglutide, sold under the brand names Wegovy and Ozempic, and tirzepatide are prescribed for weight management and treating type 2 diabetes by helping patients regulate blood sugar.

Lastly, the researchers observed that while patients who discontinued obesity medications lost significantly less weight ...

Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as ...

GLP-1 medications offer promising benefits for obesity and diabetes patients, with studies showing reduced heart attack risk ...

Medical experts reveal alarming risks as patients seek 'quick fix' weight loss injections without meeting clinical criteria, ...

A Cleveland Clinic study shows that semaglutide and tirzepatide—injectable GLP-1 drugs for obesity—produce smaller weight ...

Early-stage study results suggest that a single shot of the company’s therapy, which works differently than GLP-1 medicines, ...